818 related articles for article (PubMed ID: 15738451)
1. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
Eddy DM; Schlessinger L; Kahn R
Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
[TBL] [Abstract][Full Text] [Related]
3. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
Diabetes Prevention Program Research Group
Diabetes Care; 2003 Sep; 26(9):2518-23. PubMed ID: 12941712
[TBL] [Abstract][Full Text] [Related]
4. Summaries for patients. The cost-effectiveness of strategies to prevent type 2 diabetes.
Ann Intern Med; 2005 Mar; 142(5):I28. PubMed ID: 15738446
[No Abstract] [Full Text] [Related]
5. Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore.
Png ME; Yoong JS
PLoS One; 2014; 9(9):e107225. PubMed ID: 25203633
[TBL] [Abstract][Full Text] [Related]
6. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
7. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Diabetes Prevention Program Research Group
Diabetes Care; 2012 Apr; 35(4):723-30. PubMed ID: 22442395
[TBL] [Abstract][Full Text] [Related]
8. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
Palmer AJ; Roze S; Valentine WJ; Spinas GA; Shaw JE; Zimmet PZ
Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
[TBL] [Abstract][Full Text] [Related]
9. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.
Hernan WH; Brandle M; Zhang P; Williamson DF; Matulik MJ; Ratner RE; Lachin JM; Engelgau MM;
Diabetes Care; 2003 Jan; 26(1):36-47. PubMed ID: 12502656
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India.
Islek D; Weber MB; Ranjit Mohan A; Mohan V; Staimez LR; Harish R; Narayan KMV; Laxy M; Ali MK
JAMA Netw Open; 2020 Jul; 3(7):e207539. PubMed ID: 32725244
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
[TBL] [Abstract][Full Text] [Related]
12. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Flórez H
Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.
Zhou X; Siegel KR; Ng BP; Jawanda S; Proia KK; Zhang X; Albright AL; Zhang P
Diabetes Care; 2020 Jul; 43(7):1593-1616. PubMed ID: 33534726
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes.
Ackermann RT; Marrero DG; Hicks KA; Hoerger TJ; Sorensen S; Zhang P; Engelgau MM; Ratner RE; Herman WH
Diabetes Care; 2006 Jun; 29(6):1237-41. PubMed ID: 16732002
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.
Herman WH; Edelstein SL; Ratner RE; Montez MG; Ackermann RT; Orchard TJ; Foulkes MA; Zhang P; Saudek CD; Brown MB;
Am J Manag Care; 2013; 19(3):194-202. PubMed ID: 23544761
[TBL] [Abstract][Full Text] [Related]
19. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
Herman WH; Pan Q; Edelstein SL; Mather KJ; Perreault L; Barrett-Connor E; Dabelea DM; Horton E; Kahn SE; Knowler WC; Lorenzo C; Pi-Sunyer X; Venditti E; Ye W;
Diabetes Care; 2017 Dec; 40(12):1668-1677. PubMed ID: 29021207
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia.
Roberts S; Craig D; Adler A; McPherson K; Greenhalgh T
BMC Med; 2018 Jan; 16(1):16. PubMed ID: 29378576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
